Abstract:AdipoRon, a small-molecule adiponectin receptor (AdipoR) agonist, has been reported to be implicated in cardiovascular diseases. However, its role in pressure-overload-induced cardiac remodeling is still elusive. To elucidate the role of AdipoRon in the pathogenesis of cardiac remodeling in vivo and vitro, in the left ventricle of human end-stage heart failure, the expression of AdipoR2 is upregulated. Meanwhile, increased expression of AdipoR2 was also observed in mice failing hearts. Oral administration of AdipoRon alleviated cardiac hypertrophy and fibrosis induced by pressure overload, as evidenced by the beneficial change of cross-sectional area of cardiomyocytes, heart weight-to-body weight ratio, gene expression of hypertrophic markers, ventricle collagen ratio, and cardiac function. The AMPKα activation mediated by AdipoRon significantly inhibited AngII-induced TGF-β1 expression and cardiac fibroblast differentiation, and these inhibitory effects were abrogated by treatment with the AMPK inhibitor Compound C. Consistent with the above results, AdipoRon abolished the ability to retard AngII-induced TGF-β1 expression in AMPKα2 −/− cardiac fibroblasts. In AMPKα2 −/− mice subjected to aortic banding, AdipoRon abolished the protective effect, as indicated by increased cross-sectional area, cardiac collagen ratio, and cardiac dysfunction. Our results demonstrated that AdipoR2 expression was markedly increased in the failing hearts. AdipoRon inhibited TGF-β1 expression and myofibroblast differentiation in AMPKα-dependent manner in vitro. In line with the vitro results, AMPKα2 −/− mice markedly abrogated the inhibitory effects of AdipoRon in cardiac remodeling. These results indicated AdipoRon may hold promise of an effective therapy against pressure-overload-induced cardiac remodeling. Key messages • The increased expression of AdipoR2 is observed in human and mice failing hearts, the changeable expression of AdipoR suggests the possible role of AdipoR in cardiac remodeling. • Oral administration of AdipoRon alleviates cardiac hypertrophy and fibrosis induced by pressure overload, and AMPKα activation mediated by AdipoRon significantly inhibited AngII-induced TGF-β1 expression and cardiac fibroblast differentiation. • These findings provide new mechanistic insight and open new therapeutic pathways for heart failure.

Adiponectin receptor agonist AdipoRon modulates human and mouse platelet function

Adiponectin Receptor Agonist AdipoRon Suppresses Adipogenesis in C3H10T1/2 Cells Through the Adenosine Monophosphate-Activated Protein Kinase Signaling Pathway

Hepatoprotective effects of AdipoRon against d-galactosamine-induced liver injury in mice

AdipoRon Attenuates Hypertension-Induced Epithelial-Mesenchymal Transition and Renal Fibrosis Via Promoting Epithelial Autophagy

AdipoRon exerts opposing effects on insulin sensitivity via fibroblast growth factor 21–mediated time-dependent mechanisms

AdipoRon, an adiponectin receptor agonist, attenuates cardiac remodeling induced by pressure overload

AdipoRon Protects Against Tubular Injury in Diabetic Nephropathy by Inhibiting Endoplasmic Reticulum Stress

AdipoRon Attenuates Neuroinflammation after Intracerebral Hemorrhage Through AdipoR1-AMPK Pathway

AdipoRon Prevents L-Thyroxine or Isoproterenol-Induced Cardiac Hypertrophy Through Regulating the AMPK-related Pathway.

The Adiponectin Receptor Agonist AdipoRon Ameliorates Diabetic Nephropathy in a Model of Type 2 Diabetes.

AdipoRon prevents myostatin‐induced upregulation of fatty acid synthesis and downregulation of insulin activity in a mouse hepatocyte line

Distribution of Adiponectin Receptors in the Brain of Adult Mouse: Effect of a Single Dose of the Adiponectin Receptor Agonist, AdipoRON, on Ischemic Stroke

[AdipoRon Effect on Expression of Lipid Metabolism Genes in Cultured Human Primary Macrophages]

PEGylated AdipoRon derivatives improve glucose and lipid metabolism under insulinopenic and high-fat diet conditions

Therapeutic Effects of AdipoRon on Liver Inflammation and Fibrosis Induced by CCl4 in Mice.

Abstract 4142757: Adiponectin Receptor Agonist Alleviates Heart Failure with Preserved Ejection Fraction by Regulating NLRP3/Caspase-1/IL-1β and Pl3K/Akt Signaling Pathway

AdipoRon Inhibits Neuroinflammation Induced by Deep Hypothermic Circulatory Arrest Involving the AMPK/NF-kappa B Pathway in Rats

Adiponectin receptor agonist ameliorates cardiac lipotoxicity via enhancing ceramide metabolism in type 2 diabetic mice

AdipoRon promotes amyloid‐β clearance through enhancing autophagy via nuclear GAPDH‐induced sirtuin 1 activation in Alzheimer's disease

Discovery of AdipoRon Analogues As Novel AMPK Activators Without Inhibiting Mitochondrial Complex I.

Adiponectin Reduces Atherosclerosis in Apolipoprotein E-Deficient Mice